The visit that does not need a room

The first wave of telehealth sold convenience for minor complaints, which was a modest business. The durable version is specialty access: getting a patient to a specialist who is not within driving distance, in weeks rather than months.

Historically virtual care was reimbursed poorly and used rarely. Emergency waivers proved the delivery model worked, and the subsequent argument has been about which parts should remain covered.

The structural driver is specialist maldistribution. Specialists cluster in cities while patients do not, and the resulting wait times are a measurable harm that virtual delivery genuinely addresses.

The technology layer spans virtual consultation platforms, remote diagnostic devices that let a distant clinician examine properly, asynchronous specialist review, e consult models where a primary physician gets specialist input without referring, and the licensure and credentialing infrastructure underneath.

Adoption economics work when virtual care substitutes for something more expensive: an avoided emergency visit, a prevented transfer, a specialist opinion that stops an unnecessary referral.

The beneficiaries include virtual specialty providers, remote diagnostic device makers, credentialing and licensure platforms, health systems extending their reach, and the payers reducing out of network costs.

The value chain runs from payer and health system through platform to clinician and patient. Clinician supply and multi state licensure are the practical constraints.

The overlooked layer includes credentialing and licensure infrastructure, remote examination devices, interpretation services, and the clinician staffing platforms supplying specialists.

Competitive dynamics favour providers with health system partnerships and multi state clinician networks over direct to consumer brands, because the money and the volume are institutional.

Risks: reimbursement parity is not permanent and is revisited regularly, licensure remains state by state in some markets, clinician supply limits growth, and the category has produced large valuation collapses.

What to watch: reimbursement parity legislation, interstate licensure compact adoption, specialist wait times, and health system virtual programme launches.